As we seek a better tomorrow, here are three predictions from global life science and diagnostics company, PerkinElmer, that will lead to better health outcomes.

In this interview, Greg Gosch shares insights into the science of multiplexing, discusses how ChromaCode is redefining molecular diagnostics and explores how HDPCR is shaping the future of what’s possible in COVID-19, related respiratory and other disease testing.

Single-cell technologies are transforming our knowledge of human health and disease. In this article, Gary Kruppa outlines the latest advances in single-cell proteomics.

In this instalment of Science Futures, Rajannya discusses the real-world applications of her research and explains how technologies have steered her work.

Agilent recently announced its commitment to achieve net-zero greenhouse gas emissions no later than 2050. We spoke to them to learn how you go about making a global company with 16,300 employees a net-zero business.

While many of us are still attending events remotely, ASMS 2021 has been in full swing this year with in-person talks and events. To give you a taste of the topics proving popular this year, Technology Networks has produced a round up to highlight a selection of key themes and innovations.

To find out more about how AI can improve melanoma diagnosis, Technology Networks spoke to Dr. Kiran Motaparthi, director of dermatopathology and clinical associate professor of dermatology at the University of Florida and Julianna Ianni, PhD, vice president of AI R&D, Proscia.

The ability to detect a tumor earlier, when it is smaller, reduces the impact of surgery and treatment, improving the prognosis for many patients. Dxcover has developed a new spectroscopic liquid biopsy approach that is able to identify brain tumors as small as 0.2 cm³ from a blood sample in as little as fifteen minutes.

To find out more about HPIMS, Technology Networks spoke with Dr. Ching Wu, founder and chief executive officer at Excellims and a pioneer of HPIMS. In this interview, Dr. Wu talks about the advantages that the technique can offer in applications ranging from pharma PAT to clinical diagnostics, and discusses how Excellims is increasing accessibility to the technology.

The service will enable oncologists, hematologists and other healthcare professionals to undertake rapid and extensive genomic analysis of cancer samples on an unprecedented scale in the UK.